share_log

Northland Capital Markets Maintains Outperform on BioLife Solns, Raises Price Target to $28

Benzinga ·  Aug 10 01:37  · Ratings

Northland Capital Markets analyst Carl Byrnes maintains BioLife Solns (NASDAQ:BLFS) with a Outperform and raises the price target from $26 to $28.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment